These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 3556260)

  • 21. Bile acids and vitamin A absorption in man: the effects of two bile acid-binding agents, cholestyramine and lignin.
    Barnard DL; Heaton KW
    Gut; 1973 Apr; 14(4):316-8. PubMed ID: 4706914
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Colestipol, clofibrate, and phytosterols in combined therapy of hyperlipidemia.
    Grundy SM; Mok HY
    J Lab Clin Med; 1977 Feb; 89(2):354-66. PubMed ID: 833472
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of cholestyramine on fecal bile salt excretion in rats fed diets containing medium-chain triglycerides or corn oil.
    Hagerman LM; Schneider DL
    Proc Soc Exp Biol Med; 1973 May; 143(1):93-6. PubMed ID: 4703451
    [No Abstract]   [Full Text] [Related]  

  • 24. Absorption of dietary fats by the rat in cholestyramine-induced steatorrhea.
    Harkins RW; Hagerman LM; Sarett HP
    J Nutr; 1965 Sep; 87(1):85-92. PubMed ID: 5890965
    [No Abstract]   [Full Text] [Related]  

  • 25. Bile acid sequestrants as a therapeutic option for glucose lowering in type 2 diabetes mellitus.
    Levy P
    Endocr Pract; 2008; 14(5):644-7. PubMed ID: 18753111
    [No Abstract]   [Full Text] [Related]  

  • 26. rHDL administration increases reverse cholesterol transport in mice, but is not additive on top of ezetimibe or cholestyramine treatment.
    Maugeais C; Annema W; Blum D; Mary JL; Tietge UJ
    Atherosclerosis; 2013 Jul; 229(1):94-101. PubMed ID: 23725986
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of hypercholesterolemia.
    Grundy SM
    Am J Clin Nutr; 1977 Jun; 30(6):985-92. PubMed ID: 326023
    [No Abstract]   [Full Text] [Related]  

  • 28. [Treatment of essential hypercholesterolemia by normolipidemic drugs in children].
    Boucherle A; Calop J; Rossignol AM; Bost M
    Pediatrie; 1989; 44(8):633-6. PubMed ID: 2622704
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Indications for the pharmacologic treatment of hyperlipidemias].
    Cía Gómez P
    Rev Clin Esp; 2000 Nov; 200(11):622-5. PubMed ID: 11196593
    [No Abstract]   [Full Text] [Related]  

  • 30. Dietary fibers. III. Effects of chronic intake on cholesterol absorption and metabolism in the rat.
    Vahouny GV; Roy T; Gallo LL; Story JA; Kritchevsky D; Cassidy M
    Am J Clin Nutr; 1980 Oct; 33(10):2182-91. PubMed ID: 6252774
    [No Abstract]   [Full Text] [Related]  

  • 31. Turnover of plasma lipoprotein cholesterol.
    Myant NB
    Biochem J; 1971 Jul; 123(4):19P-20P. PubMed ID: 5126881
    [No Abstract]   [Full Text] [Related]  

  • 32. Effect of treatment with a bile-sequestering agent (Secholex) on intestinal absorption, duodenal bile acids, and plasma lipids.
    Ritland S; Fausa O; Gjone E; Blomhoff JP; Skrede S; Lanner A
    Scand J Gastroenterol; 1975; 10(8):791-800. PubMed ID: 173015
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Analytic procedures for data on whole-body metabolism of cholesterol.
    Reiner JM; Kim DN; Lee KT; Thomas WA
    Exp Mol Pathol; 1975 Feb; 22(1):65-72. PubMed ID: 1116567
    [No Abstract]   [Full Text] [Related]  

  • 34. [Hypolipidaemic agents (author's transl)].
    Tillement JP; Albengres E; Choisy H; Millart H
    Nouv Presse Med; 1980 Oct; 9(40):2947-50. PubMed ID: 7443428
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy, tolerance, and safety of colestipol HCL as a hypocholesterolemic agent in hyperlipidemic patients with studies of its effect on gastrointestinal absorption.
    Faruqui AM; Thurmond MS; Wenger J; Wenger NK
    J Pak Med Assoc; 1981 Nov; 31(11):241-5. PubMed ID: 6802993
    [No Abstract]   [Full Text] [Related]  

  • 36. Hypolipidemic drugs.
    Fleischmajer R
    Am Fam Physician; 1978 Feb; 17(2):188-90. PubMed ID: 622945
    [No Abstract]   [Full Text] [Related]  

  • 37. Mechanisms of action of cholestyramine in the treatment of hypercholesterolemia.
    Nazir DJ; Horlick L; Kudchodkar BJ; Sodhi HS
    Circulation; 1972 Jul; 46(1):95-102. PubMed ID: 5039828
    [No Abstract]   [Full Text] [Related]  

  • 38. Influence of sodium taurocholate, cholestyramine, and mylanta on the intestinal absorption of glucocorticoids in the rat.
    Ware AJ; Combes B
    Gastroenterology; 1973 Jun; 64(6):1150-5. PubMed ID: 4706135
    [No Abstract]   [Full Text] [Related]  

  • 39. Choosing the right lipid-regulating agent. A guide to selection.
    Farmer JA; Gotto AM
    Drugs; 1996 Nov; 52(5):649-61. PubMed ID: 9118815
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Choice of cholesterol-lowering drugs.
    Med Lett Drugs Ther; 1993 Mar; 35(891):19-22. PubMed ID: 8433674
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.